CD274 and adenocarcinoma: However, apparently there was a signal for better survival in the pooled analysis, and more randomized data are needed before making further conclusions about the use of IO in the adenocarcinoma subpopulation with PD-L1 CPS greater than 10% because only 163 patients overall were available for analysis (75 in the investigational arms and 88 in the experimental arms) (Supplementary Figure 8, F, available online).